Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.
Efforts to prevent Haemophilus influenzae type b (HIB) infections in infancy have been hampered by the low immunogenicity of capsular polysaccharide vaccines in children younger than 18 mos. In searching for alternate immunogens, we have studied the protective potential of polysaccharide-poor, lipid-rich endotoxin (LPS) core in experimental HIB infections. Because all gram-negative bacteria have similar LPS core structures, we were able to use as vaccine the J5 mutant of Escherichia coli 0111, the LPS of which consists only of core components, and thus to avoid problems in interpretation arising from vaccine contamination with non-LPS HIB immunogens. Mice were given graded inocula of HIB and developed lethal infection analogous to human HIB disease when virulence was enhanced with mucin and hemoglobin. After active immunization with heat-killed E. coli J5, 40/50 (80%) of infected mice survived, compared with 14/50 (28%) of saline-immunized controls (P less than 0.005). Passive immunization with rabbit antiserum against E. coli J5 prevented lethal HIB infection when administered 24 or 72 h before or 3 h after infection. This protection was abolished by adsorption of antiserum with purified J5 LPS, with survival reduced from 14/24 to 0/24 (P less than 0.005). Furthermore, rabbit antiserum to purified J5 LPS gave just as potent protection against death as antiserum to whole J5 cells. These studies demonstrate that immunity to core LPS confers protection against experimental murine HIB infection and provide the framework for a new approach to prevention of human disease from HIB.
D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000276:immunology*; D001428:Bacterial Vaccines / Q000627:therapeutic use; D002648:Child; D003429:Cross Reactions; D004926:Escherichia coli / Q000276:immunology*; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control*; D006193:Haemophilus influenzae; D006801:Humans; D007114:Immunization; D008070:Lipopolysaccharides / Q000276:immunology*
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D008070:Lipopolysaccharides